MoCRA Implementation Delay Creates More Legal Exposure For Stakeholders
By: Eileen Francis
June 26, 2025
Alkhazov explained the law “empowers and increases the FDA enforcement authority with mandatory recalls, facility suspensions and records access, which creates new potential exposure points for non-compliant companies, or companies who are kind of in that gray area and think they’re doing what needs to be done but they aren’t quite there. So that’s certainly a pain point with respect to the lack of final rules,” she said.
To read full article, click here.*
*Subscription may be required.
